November 24, 2009 (FinancialWire) — DARA BioSciences, Inc. (NASDAQ: DARA), a biopharmaceutical development company, presented clinical data results for KRN5500, its lead compound for Neuropathic Pain, which achieved its primary endpoint of pain reduction and demonstrated superior performance vs. Placebo (p=0.03).

These study results were presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held November 19-21, 2009 in San Francisco.

Sharon M. Weinstein, MD, a leading investigator in the study, presented a poster entitled “KRN5500 Demonstrates Significant Reduction in Neuropathic Pain Intensity in Patients with Cancer.” The presentation provided an overview of the results from the recently completed multicenter, placebo-controlled, blinded, randomized, parallel group study designed to evaluate the safety and efficacy of KRN5500 in patients with neuropathic pain and advanced cancer. In this study KRN5500 demonstrated clinical proof of concept by meeting the primary efficacy endpoint of pain reduction.

Dr. Weinstein is a physician at the University of Utah and Huntsman Cancer Institute in Salt Lake City, UT, and is a Fellow in the American Academy of Hospice and Palliative Medicine (FAAHPM).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.